150 related articles for article (PubMed ID: 14961584)
1. Perfusion of 99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target.
Costello B; Li C; Duff S; Butterworth D; Khan A; Perkins M; Owens S; Al-Mowallad AF; O'Dwyer S; Kumar S
Int J Cancer; 2004 Apr; 109(3):436-41. PubMed ID: 14961584
[TBL] [Abstract][Full Text] [Related]
2. CD105 is important for angiogenesis: evidence and potential applications.
Duff SE; Li C; Garland JM; Kumar S
FASEB J; 2003 Jun; 17(9):984-92. PubMed ID: 12773481
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of vascular endothelial growth factor (VEGF) does not correlate with microvessel density in renal cell carcinoma.
Raica M; Cimpean AM; Anghel A
Neoplasma; 2007; 54(4):278-84. PubMed ID: 17822316
[TBL] [Abstract][Full Text] [Related]
5. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M
Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781
[TBL] [Abstract][Full Text] [Related]
6. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model.
Fonsatti E; Jekunen AP; Kairemo KJ; Coral S; Snellman M; Nicotra MR; Natali PG; Altomonte M; Maio M
Clin Cancer Res; 2000 May; 6(5):2037-43. PubMed ID: 10815930
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody.
Tanaka F; Otake Y; Yanagihara K; Kawano Y; Miyahara R; Li M; Yamada T; Hanaoka N; Inui K; Wada H
Clin Cancer Res; 2001 Nov; 7(11):3410-5. PubMed ID: 11705856
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody.
Yao Y; Kubota T; Takeuchi H; Sato K
Neuropathology; 2005 Sep; 25(3):201-6. PubMed ID: 16193836
[TBL] [Abstract][Full Text] [Related]
9. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma.
Behrem S; Zarkovic K; Eskinja N; Jonjic N
Croat Med J; 2005 Jun; 46(3):417-22. PubMed ID: 15861521
[TBL] [Abstract][Full Text] [Related]
10. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies.
Matsuno F; Haruta Y; Kondo M; Tsai H; Barcos M; Seon BK
Clin Cancer Res; 1999 Feb; 5(2):371-82. PubMed ID: 10037187
[TBL] [Abstract][Full Text] [Related]
11. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis.
Li C; Gardy R; Seon BK; Duff SE; Abdalla S; Renehan A; O'Dwyer ST; Haboubi N; Kumar S
Br J Cancer; 2003 May; 88(9):1424-31. PubMed ID: 12778073
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography imaging of CD105 expression during tumor angiogenesis.
Hong H; Yang Y; Zhang Y; Engle JW; Barnhart TE; Nickles RJ; Leigh BR; Cai W
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1335-43. PubMed ID: 21373764
[TBL] [Abstract][Full Text] [Related]
13. [The immunohistochemical expression of CD105 is a marker for high metastatic risk and worse prognosis in breast cancers].
Charpin-Taranger C; Dales JP; Garcia S; Andrac-Meyer L; Ramuz O; Carpentier-Meunier S; Bonnier P
Bull Acad Natl Med; 2003; 187(6):1129-45; discussion 1145-6. PubMed ID: 14978873
[TBL] [Abstract][Full Text] [Related]
14. Irradiation induces up-regulation of E9 protein (CD105) in human vascular endothelial cells.
Wang JM; Kumar S; van Agthoven A; Kumar P; Pye D; Hunter RD
Int J Cancer; 1995 Sep; 62(6):791-6. PubMed ID: 7558432
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1998; 18(3A):1485-500. PubMed ID: 9673360
[TBL] [Abstract][Full Text] [Related]
16. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels.
Fonsatti E; Altomonte M; Nicotra MR; Natali PG; Maio M
Oncogene; 2003 Sep; 22(42):6557-63. PubMed ID: 14528280
[TBL] [Abstract][Full Text] [Related]
17. Lack of specificity of endoglin expression for tumor blood vessels.
Balza E; Castellani P; Zijlstra A; Neri D; Zardi L; Siri A
Int J Cancer; 2001 Nov; 94(4):579-85. PubMed ID: 11745447
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis and metastasis marker of human tumors.
Seon BK; Takahashi N; Haba A; Matsuno F; Haruta Y; She XW; Harada N; Tsai H
Rinsho Byori; 2001 Oct; 49(10):1005-13. PubMed ID: 11769465
[TBL] [Abstract][Full Text] [Related]
19. In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis.
Yang Y; Zhang Y; Hong H; Liu G; Leigh BR; Cai W
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):2066-76. PubMed ID: 21814852
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]